PharmStar Pharmaceuticals, Inc. (PINKSHEETS: PHAR), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, announced today that its CEO Howard Phykitt will be holding an investor's Conference Call on Monday, July 18, 2011 at 11:00 AM EDT.

All interested parties are encouraged to attend, as Mr. Phykitt will provide an update on the status of the company, and will discuss the recently announced line extensions that the company is developing. Anyone with questions is encouraged to submit them by email to conferencecall@pharmstarinc.com. Time permitting, Mr. Phykitt will answer all questions related to the company.

To participate in the Conference Call, please dial 712-432-3900, then enter 594265# when prompted for the conference ID. Please join the call about 5 minutes early, as the call will begin promptly at 11:00 AM EDT.

Also, Mr. Phykitt will be appearing on the Bill Chippas Show tonight at 6:15 PM to further discuss the new line of products in development. You can listen in by visiting billchippasshow.com, and click on the listen live link.

About PharmStar
Pharmaceuticals PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved, OTC liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. For more information, visit www.pharmstarinc.com.

Forward-Looking Statements Disclosure This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "will," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.